NCT03755167 - A Follow up Study to Protocol 101/2 - Continued Treatment by IPL344 IV | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 9, 2018

Primary Completion Date

January 31, 2027

Study Completion Date

February 28, 2027

Conditions

Amyotrophic Lateral Sclerosis (ALS)

Interventions

DRUG

IPL344

IPL344 will be administered by intravenously (IV) infusion once a day (every 24±6 hours), using a Peripherally Inserted Central Catheter (PICC) line or a permanent port. IPL344 will be administered using an electronic pump at a flow rate that will be determined in protocol 101/2. The dose will be fixed as MTD as established in protocol 101/2 (up to 3.2 mg/kg).

Trial Locations (2)

91120

Hadassah Medical Center/Neuromuscular / EMG service and ALS / Motor Neuron Disease Clinic, Jerusalem

Unknown

Hadassah Medical Center -Motor Neuron Disease Clinic, Jerusalem